
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Tenax Therapeutics Inc (TENX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: TENX (1-star) is currently NOT-A-BUY. Pass it for now.
Year Target Price $18.85
Year Target Price $18.85
3 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Under performing |
0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.27% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.27M USD | Price to earnings Ratio 3.46 | 1Y Target Price 18.85 |
Price to earnings Ratio 3.46 | 1Y Target Price 18.85 | ||
Volume (30-day avg) - | Beta 1.62 | 52 Weeks Range 2.80 - 7.89 | Updated Date 06/29/2025 |
52 Weeks Range 2.80 - 7.89 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.6% | Return on Equity (TTM) -39.78% |
Valuation
Trailing PE 3.46 | Forward PE 0.3 | Enterprise Value 15163482 | Price to Sales(TTM) - |
Enterprise Value 15163482 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.14 | Shares Outstanding 4148500 | Shares Floating 4091921 |
Shares Outstanding 4148500 | Shares Floating 4091921 | ||
Percent Insiders 0.23 | Percent Institutions 66.59 |
Analyst Ratings
Rating 4.75 | Target Price 18.85 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tenax Therapeutics Inc

Company Overview
History and Background
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products for critical care markets. Originally incorporated as Oxygen Biotherapeutics, Inc. in 2004, the company changed its name to Tenax Therapeutics, Inc. in 2014. It has focused on developing levosimendan for various indications.
Core Business Areas
- Pharmaceutical Development: Focuses on developing and commercializing levosimendan for the treatment of pulmonary hypertension and other cardiovascular conditions.
Leadership and Structure
The leadership team consists of key executives responsible for the company's strategy, operations, and clinical development programs. The organizational structure includes departments for research and development, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Levosimendan (Istaroxime): Levosimendan is a calcium sensitizer and KATP channel opener being developed for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF) and other cardiovascular conditions. Market share data is not publicly available as it is still in development. Competitors include companies developing treatments for pulmonary hypertension and HFpEF, such as Actelion Pharmaceuticals (now part of Johnson & Johnson) and Novartis.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with a focus on developing new therapies for unmet medical needs. The market for cardiovascular drugs is significant and growing, driven by aging populations and increasing prevalence of heart disease and pulmonary hypertension.
Positioning
Tenax Therapeutics is positioned as a company focused on developing novel therapies for critical care markets, specifically cardiovascular conditions. Its competitive advantage lies in its proprietary formulation of levosimendan and its potential to address unmet medical needs in pulmonary hypertension and HFpEF.
Total Addressable Market (TAM)
The TAM for treatments targeting pulmonary hypertension and HFpEF is estimated to be in the billions of dollars. Tenax Therapeutics is positioned to capture a portion of this market with successful development and commercialization of levosimendan.
Upturn SWOT Analysis
Strengths
- Proprietary formulation of levosimendan
- Focus on unmet medical needs in cardiovascular conditions
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- High regulatory hurdles
Opportunities
- Potential for breakthrough therapy designation
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Competition from established pharmaceutical companies
- Failure to obtain regulatory approval
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- JNJ
- NVS
- MRK
Competitive Landscape
Tenax Therapeutics faces significant competition from established pharmaceutical companies with greater resources and established products. Its competitive advantage lies in its proprietary formulation of levosimendan and its focus on unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's development stage.
Future Projections: Future growth depends on the successful development and commercialization of levosimendan and other potential therapies.
Recent Initiatives: Recent initiatives include clinical trials for levosimendan in pulmonary hypertension and HFpEF and securing funding for research and development activities.
Summary
Tenax Therapeutics is a development-stage pharmaceutical company focused on cardiovascular conditions, particularly pulmonary hypertension. Its future success hinges on the positive outcomes of its clinical trials and subsequent regulatory approvals for levosimendan. The company operates in a competitive market and faces challenges related to financial resources and regulatory hurdles. Successful commercialization could lead to significant growth, but risks remain high.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Press releases
- Analyst reports
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tenax Therapeutics Inc
Exchange NASDAQ | Headquaters Chapel Hill, NC, United States | ||
IPO Launch date 1997-01-02 | CEO, President & Director Mr. Christopher T. Giordano | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.tenaxthera.com |
Full time employees 4 | Website https://www.tenaxthera.com |
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.